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A B S T R A C T
Purpose
The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1)
trial (ClinicalTrials.gov identiﬁer, NCT01458548) established sequential treatment with four cycles of
rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative
disorder (PTLD) and identiﬁed response to rituximab induction as a prognostic factor for overall
survival. We hypothesized that rituximab consolidation might be sufﬁcient treatment for patients
with a complete response after rituximab induction.
Patients and Methods
In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant
recipients, with CD20+ PTLD unresponsive to immunosuppression reduction, were treated with four weekly
doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab
consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21
days. Theprimaryendpointwas treatment efﬁcacymeasuredas the response rate in patientswhocompleted
therapy and the response duration in those who completed therapy and responded. Secondary end points
were frequencyof infections, treatment-relatedmortality, andoverall survival in the intention-to-treat population.
Results
One hundred eleven of 126 patients had a complete or partial response (88%; 95%CI, 81% to 93%),
of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was
not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6
years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related
mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to
rituximab induction remained a prognostic factor for overall survival despite treatment stratiﬁcation.
Conclusion
In B-cell PTLD, treatment stratiﬁcation into rituximab or rituximab plus CHOP consolidation on the
basis of response to rituximab induction is feasible, safe, and effective.
J Clin Oncol 35:536-543. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Post-transplant lymphoproliferative disorders
(PTLDs) are a serious but rare consequence of
immunosuppression after solid organ trans-
plantation (SOT). Their rarity, variety of histo-
logic manifestations, and the complex medical
history of patients with PTLD have slowed the
development of evidence-based therapies. For all
of the rarer subtypes and in the relapsed or re-
fractory setting, case reports and small case series
remain the only source of evidence.1,2
Although the histologic range stretches from
polymorphic PTLD to monomorphic lymphoma-
type PTLD, the majority of cases are of CD20+
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B-cell lineage.3 In pediatric CD20+ PTLD, favorable results have
been reported in a phase II trial of rituximab, cyclophosphamide,
and corticosteroids.4 Through international cooperation, we have
been able to assemble adult patient cohorts large enough for
meaningful ﬁrst-line therapy trials. The phase II Sequential Treat-
ment of CD20-Positive Post-Transplant Lymphoproliferative Dis-
order (PTLD-1) trial recruited 70 patients from 2003 to 2007 and
established sequential treatment (ST) with four cycles of weekly
rituximab followed by four cycles of chemotherapy with cy-
clophosphamide, doxorubicin, vincristine, and prednisone
every 21 days (CHOP-21) as a standard in CD20+ PTLD after SOT.5
Median overall survival (OS) was 6.6 years, a clear improvement
over the preceding smaller rituximab monotherapy trials (1.2 to
3.5 years).6-8 Toxicity, particularly treatment-related mortality
(TRM), was 13%, thus lower than in the preceding retrospective
case series of ﬁrst-line chemotherapy in PTLD (up to 31%).5,9-15
We observed that response to four cycles of rituximab in-
duction was a prognostic factor for OS after completion of ST.5 On
this basis, we hypothesized that rituximab consolidation might be
sufﬁcient treatment for patients with a complete response (CR)
after rituximab induction. The PTLD-1 protocol was therefore
amended in 2006 to introduce risk-stratiﬁed sequential treatment
(RSST) with rituximab consolidation for patients in CR after
rituximab induction. Treatment of patients not in CR after four
weekly cycles of rituximab was changed from CHOP-21 to rit-
uximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone every 21 days (R-CHOP-21). The rationale for the
latter had several components; large trials in immunocompetent
patients with diffuse large B-cell lymphoma (DLBCL) demon-
strated a higher efﬁcacy of R-CHOP than CHOP.16,17 Moreover,
safety concerns with regard to the use of R-CHOP in immuno-
suppressed patients at the time the protocol for PTLD-1 was
developed in 2002 started to be allayed by 2006.18 The goal of this
trial was to demonstrate the feasibility, safety, and efﬁcacy of RSST
on the basis of patient response to rituximab induction.
PATIENTS AND METHODS
In 2006, after inclusion of 70 patients, the second planned interim analysis
of the PTLD-1 trial (ClinicalTrials.gov identiﬁer, NCT01458548) was
performed, and response to four courses of rituximab was identiﬁed as
a prognostic factor for OS.5 The protocol was amended to introduce RSST,
the results of which are reported in this article. The trial design outside the
treatment schedule remained unchanged. The trial was stopped after it had
reached its target recruitment (225 patients in total, 150 treated with
RSST).
Study Design and Patients
An international, prospective, multicenter, open-label, phase II trial
was performed at 32 centers in Germany, Belgium, France, Australia,
Poland, and Italy. Treatment-naive adult SOT recipients diagnosed with
CD20+ PTLD were enrolled after activation of the amendment in their
participating country from October 24, 2006, until October 3, 2014.
Inclusion and exclusion criteria remained unchanged from the original
PTLD-1 trial5 and also included response failure to upfront immuno-
suppression reduction (with or without antiviral therapy), measurable
disease . 2 cm in diameter (and/or bone marrow involvement), and an
Eastern Cooperative Oncology Group performance status # 2. The extent
and duration of upfront immunosuppression reduction were at the
discretion of the treating physician, but usually calcineurin inhibitors were
reduced by 30% to 50%, and azathioprine or mofetil mycophenolate were
stopped. Response failure to immunosuppression reduction was deﬁned as
stable disease at 2 to 4 weeks after immunosuppression reduction or as
progressive disease at any time. The main exclusion criteria were CNS
involvement, a history of HIV infection, and the presence of severe organ
dysfunction not related to PTLD.
Diagnostic tissue samples were reviewed by an expert hema-
topathologist and classiﬁed according to 2004 WHO criteria. Epstein-Barr
virus (EBV) association was conﬁrmed by in situ hybridization for EBV-
encoded small RNA transcripts. Disease stage at enrollment was de-
termined through a complete patient history; physical examination;
laboratory investigations (including full blood count, lactate de-
hydrogenase [LDH] activity and renal and liver function tests); bonemarrow
biopsy ﬁndings; cerebrospinal ﬂuid analysis; and computed tomography
(CT) scans of the head, chest, and abdomen. The responsible local ethics
committees approved the trial, and all patients gave written informed
consent according to the Declaration of Helsinki.
Treatment Plan
Treatment consisted of rituximab (375 mg/m2 intravenously [IV]) on
days 1, 8, 15, and 22 followed by interim staging by CT scan (days 40 to 50;
Fig 1). Starting on day 50, patients with CR at interim staging (low-risk
group) continued with four courses of rituximab monotherapy (375 mg/m2
IV) every 21 days, whereas all others (high-risk group) received four cycles of
R-CHOP-21 (rituximab 375mg/m2 IVon day 1, cyclophosphamide 750mg/m2
IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2
[maximum, 2 mg] IVon day 1, and prednisone 50 mg/m2 orally on days 1
through 5, every 21 days). In case of clinical signs of disease progression at
any time during rituximabmonotherapy or before interim staging, restaging
was performed prematurely, and R-CHOP-21 was commenced immediately
if disease progression was conﬁrmed. Supportive treatment with granulocyte
colony-stimulating factor after R-CHOP-21 chemotherapy was obligatory.
Pneumocystis jirovecii chemoprophylaxis was recommended. The ﬁnal
Rituximab VIII (day 116)
Rituximab VII (day 94)
Rituximab VI (day 72)
R-CHOP-21 IV (day 116)
R-CHOP-21 III (day 94)
R-CHOP-21 II (day 72)
Rituximab V (day 50)R-CHOP-21 I (day 50)
Yes: low riskNo: high risk
Rituximab IV (day 22)
Rituximab III (day 15)
Rituximab II (day 8)
Rituximab I (day 1)
CT staging:
complete
response?
Fig 1. Risk-stratiﬁed sequential treatment schedule. Rituximab signiﬁes ritux-
imab 375 mg/m2 intravenously (IV), R-CHOP-21 signiﬁes rituximab 375 mg/m2 IV
on day 1 plus cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV
on day 1, vincristine 1.4 mg/m2 (maximum, 2 mg) IV on day 1, and prednisone
50mg/m2 orally on days 1 through 5, every 21 days. In case of progressive disease
from day 1 through day 50, patients proceeded to R-CHOP-21 immediately. CT,
computed tomography.
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response assessment was performed 1 month (6 7 days) after the last cycle
of therapy. Subsequently, patients underwent follow-up examinations
every 3 months for 2 years, every 6 months for years 3 through 5, and
annually thereafter. Interim, ﬁnal response, and follow-up assessments
included a complete patient history, physical examination, laboratory
investigations, and CT scans of the chest and abdomen. Further in-
vestigations, such as bone marrow biopsy, CT scans of the head, or en-
doscopy, were performed if clinically indicated to determine remission
status. Follow-up data were evaluated up to July 2015, with a median
follow-up of 4.5 years.
Statistical Analysis
The primary end point was treatment efﬁcacy measured as response
rate in patients who completed therapy and response duration (RD) in
those who completed therapy and responded. Secondary end points were
frequency of infections, TRM, OS, and time to progression (TTP) in the
intention-to-treat (ITT) population. Response to treatment and disease
progression were classiﬁed according to WHO criteria using CT imaging.
RD was deﬁned from the date of best response (CR or partial response) to
disease progression, whereas TTP was deﬁned from start of treatment to
disease progression (all patients). OS was deﬁned from start of treatment
to death attributable to any cause. Adverse events and serious adverse
events were documented according to the WHO toxicity grading scale.
Analysis was by ITT.
CIs and best point estimates for observed response rates were cal-
culated using the adjusted Wald method. Time-to-event outcomes were
described using Kaplan-Meier statistics. Exploratory analyses were per-
formed using two-sided stratiﬁed log-rank tests as well as x2 tests for
categorical variables, and the independent samples Kruskal-Wallis test was
used for continuous variables. Multivariable analyses were performed with
Cox regression models (log-rank ratio test, backward elimination). The
two-sided signiﬁcance level was set at .05, and SPSS 22.0.0.0 statistical
software (IBM Corporation, Chicago, IL) was used for all analyses. The
results of the 70 patients treated with the original PTLD-1 trial protocol
(the ST cohort)5 and its subgroups (on the basis of rituximab response)
were used for post hoc comparisons of efﬁcacy, survival, and toxicity.
RESULTS
Patients
One hundred ﬁfty-two patients were enrolled at centers in
Germany (72 patients), Belgium (36 patients), France (24 patients),
Australia (seven patients), Poland (seven patients), and Italy (six
patients). Their baseline characteristics are listed in Table 1. Median
age was 56.4 years (range, 18 to 82 years). Sixty-nine patients had
undergone kidney transplantation, 40 patients had undergone liver
transplantation, 18 patients had undergone lung transplantation,
15 patients had undergone heart transplantation, ﬁve patients had
undergone heart and kidney transplantation, three patients had
undergone kidney and pancreas transplantation, and two patients
had undergone heart and lung transplantation. Median time from
transplantation to PTLD was 9.0 years. Most patients (112 of 152
[74%]) were diagnosed with monomorphic DLBCL-type PTLD,
67 of 144 (47%) had EBV-associated tumors and 101 of 151 (67%)
had Ann Arbor Conference classiﬁcation of disease stage III or IV.
Ninety-seven (65%) of 150 patients had an elevated serum LDH
activity at diagnosis, and 55 (38%) of 143 had an international
prognostic index (IPI) score of$ 3 (risk factors are age. 60 years,
Ann Arbor stage $ III, Eastern Cooperative Oncology Group
performance status $ 2, elevated LDH, and more than one
extranodal disease manifestation).19 Four patients were
reclassiﬁed with a diagnosis other than CD20+ PTLD on pathology
review.
Treatment
Of the 152 patients enrolled, one died before the start of
treatment. One hundred forty-eight patients could be evaluated for
Table 1. Baseline Characteristics of Patients Enrolled (intention-to-treat
population [n = 152])
Characteristic No. (%)
Median age (range), years 56.4 (18-82)
$ 60 years of age 60 (40)
Male 115 (76)
Transplant type
Kidney 69 (45)
Liver 40 (26)
Lung 18 (12)
Heart 15 (10)
Heart and kidney 5 (3)
Kidney and pancreas 3 (2)
Heart and lung 2 (1)
Median time from transplantation
to PTLD (range), years
9.0 (0.2-27.9)
, 1 year 32 (21)
$ 1 year 120 (79)
Histology
Early lesion 2 (1)
Polymorphic 20 (15)
Monomorphic 129 (85)
Burkitt 6 (4)
DLBCL 112 (74)
Other B-cell, CD20+ 8 (5)
Other B-cell, CD202* 3 (2)
Multicentric Castleman disease* 1 (1)
EBV association (n = 144)
EBV associated 67 (47)
Non–EBV associated 77 (53)
Ann Arbor Conference classiﬁcation
of disease stage (n = 151)
I 30 (20)†
II 20 (13)
III 22 (15)
IV 79 (52)
Lactate dehydrogenase (n = 150)
Within normal range 53 (35)
Elevated 97 (65)
Nodal disease (n = 151) 110 (73)
Extranodal disease (n = 151) 108 (72)
GI 43 (28)
Liver 34 (23)
Lung 26 (17)
Kidney 4 (3)
Bone marrow 12 (8)
Graft 13 (9)‡
International prognostic index (n = 143)
, 3 88 (62)
$3 55 (38)
ECOG performance status (n = 144)
0 40 (28)
1 66 (46)
2 32 (22)
3 6 (4)
Abbreviations: DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus;
ECOG, Eastern Cooperative Oncology Group; PTLD, post-transplant lympho-
proliferative disorder.
*Diagnosis changed upon pathology review.
†This includes 21 patients in stage IE.
‡Eight of 13 were patients who had undergone lung transplantation.
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response to rituximab induction, 134 of whom had received all
four scheduled applications (Fig 2). Thirty-seven (25%) of 148
patients achieved CR at interim staging and were allocated to
rituximabmonotherapy consolidation in the low-risk group. Three
of these patients did not receive further treatment—one patient
choose to withdraw from further treatment, one was withdrawn
after GI perforation, and one died as a result of pulmonary
hemorrhage. Thus, 34 patients received rituximab monotherapy
consolidation. Of the 111 patients who were not in CR after rit-
uximab induction (high-risk group), 100 went on to receive
treatment with R-CHOP-21. Two patients died before treatment
continuation (carotid perforation and liver abscesses). Nine pa-
tients were withdrawn from treatment because of: progressive
disease that involved the CNS (two patients); renal failure (two
patients); physician choice in favor of radiotherapy (two patients,
both of whom in partial response); and GI perforation, hepatitis B
viral infection, and hypokinetic cardiomyopathy (one patient
each). Ninety-two patients could be evaluated for response to
R-CHOP-21. Four patients died during therapy. Three patients
were withdrawn from therapy as a result of infectious complica-
tions, and one patient was lost to follow-up.
Although early PTLD, EBV association, and low baseline IPI
were signiﬁcantly more common in the low-risk group than in the
high-risk group (Data Supplement), 31 of 37 patients in the low-
risk group had monomorphic PTLD, 21 of 37 had late PTLD, 13 of
36 had EBV-negative tumors, and eight of 34 had an IPI $ 3. Of
note, six of 18 patients with PTLD who had undergone lung
transplantation, a subgroup with historically poor OS,20 were
allocated to the low-risk group.
Outcome
The overall response rate (ORR) of RSSTwas 88% (111 of 126
patients; 95% CI, 81% to 93%) and the CR rate was 70% (88 of
126; 95% CI, 61% to 77%). Median RD (Fig 3A) was not reached;
the 3-year Kaplan-Meier estimate was 82% (95% CI, 74% to 90%).
In the ITT population (152 patients), median TTP (Fig 3B) was not
reached. The 3-year Kaplan-Meier estimate was 75% (95%CI, 67%
to 82%). Median OS (Fig 3C) was 6.6 years (95% CI, 5.5 to
7.6 years) with a 3-year estimate of 70% (95% CI, 62% to 77%).
These results were conﬁrmed by a per-protocol analysis (Data
Supplement).
Toxicity
Fifty-seven (63%) of 91 patients experienced grade 3 or 4
leukopenia (95% CI, 52% to 72%; no repeat blood counts in 60
patients), whereas 52 (34%) of 151 patients experienced grade 3 or
4 infections (95% CI, 27% to 42%). The most common infection
experienced by patients was febrile neutropenia (24 patients),
whereas Clostridium difﬁcile colitis, P jirovecii pneumonia (PcP),
and invasive aspergillosis were experienced by three patients each.
At least two of the patients with PcP did not receive prophylaxis,
and two of those who experienced PcP were low-risk patients.
Twelve (8%) of 151 patients experienced treatment-related mor-
tality (95% CI, 5% to 14%). Five patients died as a result of in-
fections, two each from hemorrhage and the sequelae of GI
perforation and one as a result of an unknown cause. During the
follow-up period, one patient experienced fatal progressive mul-
tifocal leukencephalopathy and one patient experienced secondary
acute myeloid leukemia. Only ﬁve of 52 patients who experienced
grade 3 or 4 infections were in the low-risk group, and all but one
treatment-related death occurred in the high-risk group.
Prognostic Factors
Response to four applications of rituximab was a highly
signiﬁcant predictor of TTP and OS despite treatment stratiﬁcation
(n = 148; both P , .001; Data Supplement). We can conﬁrm the
signiﬁcance of the baseline IPI (, 3 or$3) previously reported as
Died before
start of treatment  (n = 1)
Discontinued
Lost to follow-up
(n = 2)
(n = 1)
Enrolled in cohort
for OS, TTP (N = 152) 
Started
rituximab induction (n = 151)
Evaluated for
response to rituximab (n = 148)
Not in CR (n = 111) In CR (n = 37)
Died
Discontinued 
Lost to follow-up
(n = 4)
(n = 3)
(n = 1)
Received
R-CHOP-21 (n = 100)
Received rituximab
consolidation (n = 34)
Evaluated
for response (n = 92)
Evaluated
for response (n = 34)
Died
Discontinued
(n = 1)
(n = 2)
Died
Discontinued
(n = 2)
(n = 9)
Fig 2. Diagram of number of patients
enrolled, treated, and evaluated for re-
sponse. CR, complete response; ITT,
intention to treat; OS, overall survival;
R-CHOP-21, rituximab plus cyclophos-
phamide, doxorubicin, vincristine, and
prednisone; TTP, time to progression.
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a signiﬁcant prognostic factor for OS in PTLD-1 ST21 in the RSST
cohort for TTP and OS (complete IPI data available in 143 patients;
P = .001; Data Supplement). On the other hand, there was no
signiﬁcant difference in ORR between EBV-positive and EBV-
negative PTLD (48 [86%] of 56 patients and 59 [92%] of 64
patients; P = .255). No signiﬁcant differences in TTP (P = .908) or
OS (P = .793) were found (Data Supplement). In a multivariable
analysis (Data Supplement), both response to four applications of
rituximab and the baseline IPI (, 3 or$3) were highly signiﬁcant
independent prognostic factors for TTP and OS.
Comparison With PTLD-1 ST
Baseline characteristics of both trial cohorts were similar, and
the only signiﬁcant difference was time from transplant to PTLD
(Data Supplement). The overall response rate of RSST was 111
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Fig 3. Response duration, time to progression, and overall survival. Median time of follow-up was 4.5 years. (A) Response duration (patients in complete response or
partial response). (B) Time to progression (all patients). (C) Overall survival (all patients).
540 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Trappe et al
Downloaded from ascopubs.org by University of Queensland on March 13, 2017 from 130.102.082.067
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
(88%) of 126 patients compared with 53 (90%) of 59 patients in
the PTLD-1 ST cohort.5 Median OS was identical (6.6 years), and
3-year Kaplan-Meier estimate was 70% (95% CI, 62% to 77%)
compared with 61% (95% CI, 49% to 72%) in PTLD-1 ST. The
comparisons for RD (3-year estimates, 82% [95%CI, 74% to 90%]
v 74% [95% CI, 62% to 86%]) and TTP (3-year estimates, 75%
[95% CI, 67% to 82%] v 69% [95% CI, 57% to 80%]) were fa-
vorable. The frequency of both grade 3 or 4 infections (34% v 41%)
and TRM (8% v 13%) were lower in RSST.
Low-Risk Group and Comparison With PTLD-1 ST
The TTP estimate in the low-risk rituximab consolidation
group was 89% (95% CI, 76% to 100%) at 3 years compared with
69% (95% CI, 44% to 95%) in the 14 patients in PTLD-1 ST who
had reached CR with rituximab induction and continued ST with
CHOP chemotherapy (Fig 4A). OS in these two cohorts was similar,
with 3-year Kaplan-Meier estimates of 91% (95%CI, 82% to 100%)
and 86% (95% CI, 67% to 100%), respectively (Fig 4B). An
analogous comparison of the high-risk R-CHOP consolidation
group with patients in the PTLD-1 ST group who had not reached
CR after rituximab induction can be found in the Data Supplement.
DISCUSSION
When published in 2012, the PTLD-1 ST trial with 70 patients had
been the largest prospective trial in PTLD and demonstrated an
unprecedented median OS of 6.6 years.5 We present the results of
a prospective trial with more than twice as many patients recruited
in six countries from a wide range of clinical settings.
The results of the 70 patients treated with ST in the PTLD-1
trial from 2003 to 2007 provide a suitable benchmark. Despite the
limiting of chemotherapy to the high-risk group, the ORR of 88%
andmedian OS of 6.6 years of RSST closely match the results of ST,
where all patients received CHOP chemotherapy. Furthermore, the
Kaplan-Meier estimates of RD, TTP, and OS compare favorably,
and the infection andmortality safety parameters were lower in the
RSST cohort.
The 3-year TTP of 89% (95% CI, 76% to 100%) in the low-
risk rituximab consolidation group conﬁrmed the key hypothesis
of this protocol—ACR to rituximab induction identiﬁes a group of
patients with B-cell PTLD who do not need chemotherapy. This is
further supported by our observation that response to rituximab
monotherapy is a predictive marker for OS and TTP.
The safety proﬁle of RSST was favorable. TRM was 8% and
thus comparable to that reported in immunocompetent patients
with DLBCL older than 60 years of age (7% with six cycles of
R-CHOP every 14 days in RICOVER-60 [Six Versus Eight Cycles of
Biweekly CHOP-14With orWithout Rituximab in Elderly Patients
With Aggressive CD20+ B-Cell Lymphomas] and 6% with eight
cycles of CHOP-21 with or without rituximab in LNH98.5 [CHOP
Chemotherapy Plus Rituximab Compared With CHOP Alone in
Elderly Patients With DLBCL]).16,22 R-CHOP immunochemo-
therapy in the high-risk patients did not result in excess toxicity or
mortality. We conclude that R-CHOP, the proven standard in
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Fig 4. Patients in complete response after rituximab induction (low-risk group). Time to progression and overall survival in the risk-stratiﬁed sequential treatment (RSST)
cohort (n = 37; solid line) and the sequential treatment (ST) cohort (n = 14; dashed line). (A) Time to progression. The 3-year Kaplan-Meier estimate was 89% (95%CI, 76%
to 100%) compared with 69% (95% CI, 44% to 95%) in the 14 patients in the PTLD-1 (Sequential Treatment of CD20-Positive Post-Transplant Lymphoproliferative
Disorder trial) ST cohort. (B) Overall survival. The 3-year Kaplan-Meier estimate was 70% (95% CI, 62% to 77%) compared with 61% (95% CI, 49% to 72%) in PTLD-1 ST
cohort. Of the six late deaths that occurred in the RSST low-risk cohort, two were attributable to progressive PTLD (after ﬁrst and second relapse) whereas four were not
(one death as a result of unknown causes and three as a result of infections).
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immunocompetent patients with CD20+ DLBCL16,17,22 can be
safely used in PTLD as part of ST. However, the spectrum of
infections observed included entities typically associated with
longstanding immunosuppression (PcP, aspergillosis, progressive
multifocal leukencephalopathy).23-25
The optimal treatment of PTLD has long been a source of
controversy.26 This study lend further support to the argument that
B-cell PTLD should not be treated with upfront R-CHOP
immunochemotherapy in analogy with immunocompetent pa-
tients with DLBCL. Upfront chemotherapy in PTLD, to our
knowledge, has never been tested in a prospective setting. In
retrospective case series of CHOP or CHOP-like protocols, TRM
has been reported to be as high as 26% and 31%.12,15 We observed
a more acceptable rate of TRM (13%) in our previous prospective
trial of ST, where CHOP was administered after rituximab in-
duction, possibly as a result of reduced tumor burden and a delay of
50 days between reduction of immunosuppression and start of
chemotherapy.5 The current trial demonstrates that approximately
25% of patients with PTLD do not need chemotherapy.
Furthermore, the results with continued rituximab strongly
suggest that rituximab consolidation is superior to no consoli-
dation (ie, that eight, not four, courses of rituximab are the best
available therapy for patients in CR after rituximab induction).
Althoughwe have not formally tested this hypothesis, the TTP with
RSST in the low-risk group (97% at 24 months; Fig 4A) compares
favorably with previous trials where only four cycles of rituximab
were administered. In the German and French rituximab mon-
otherapy trials, four of 25 patients in CR experienced a relapse
within 12 months, and Blaes et al reported a median duration of
CR of 8 months.27,28
In summary, this study establishes the feasibility, efﬁcacy, and
safety of RSST in CD20+ PTLD. In the absence of any randomized
trial data, the results deﬁne RSST as a new therapeutic standard in
adult CD20+ PTLD after SOT and demonstrate that PTLD is
a successfully treatable lymphoma.
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